VIIV Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VIIV, and when can generic versions of VIIV drugs launch?
VIIV has twenty-six approved drugs.
There are twelve US patents protecting VIIV drugs.
There are five hundred and fourteen patent family members on VIIV drugs in fifty-nine countries and two hundred and eleven supplementary protection certificates in eighteen countries.
Summary for VIIV
International Patents: | 514 |
US Patents: | 12 |
Tradenames: | 19 |
Ingredients: | 17 |
NDAs: | 26 |
Patent Litigation for VIIV: | See patent lawsuits for VIIV |
PTAB Cases with VIIV as patent owner: | See PTAB cases with VIIV as patent owner |
Drugs and US Patents for VIIV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | TIVICAY PD | dolutegravir sodium | TABLET, FOR SUSPENSION;ORAL | 213983-001 | Jun 12, 2020 | RX | Yes | Yes | 8,129,385*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | RX | Yes | Yes | 8,129,385*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-002 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for VIIV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | RESCRIPTOR | delavirdine mesylate | TABLET;ORAL | 020705-002 | Jul 14, 1999 | 5,563,142 | ⤷ Try a Trial |
Viiv Hlthcare | RETROVIR | zidovudine | CAPSULE;ORAL | 019655-001 | Mar 19, 1987 | 4,828,838 | ⤷ Try a Trial |
Viiv Hlthcare | RETROVIR | zidovudine | CAPSULE;ORAL | 019655-001 | Mar 19, 1987 | 4,833,130 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
International Patents for VIIV Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2009541271 | ⤷ Try a Trial |
South Africa | 200803423 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2012037320 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for VIIV Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1284974 | C300338 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MARAVIROC, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/07/418/001-010 20070918 |
1663240 | 122015000087 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINER THERAPEUTISCH AEQUIVALENTEN FORM DAVON, DIE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE Z.B EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, UND TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
1663240 | 222 6-2015 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: EMTRICITABIN/RILPIVIRINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/737/001 - EU/1/11/737/002 20111128 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.